NSE: SPARC · BSE: 532872 · ISIN INE232I01014
Sun Pharma Advanced Research Company Limited stock analysis
Sun Pharma Advanced Research Company Limited ranks #158 in the TickerSutra evidence-ranked universe with a score of 71/100 and 95% data confidence. The latest captured fundamentals show ROCE of 165.0%, quarterly sales growth of 314.1% and quarterly profit growth of 59.7%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 165%
- 98.8% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
- Extreme base-effect growth requires manual validation
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹137cr | ₹-187cr | ₹-203cr | -136.0% |
| 2023 | ₹239cr | ₹-214cr | ₹-223cr | -90.0% |
| 2024 | ₹76cr | ₹-404cr | ₹-388cr | -534.0% |
| 2025 | ₹72cr | ₹-327cr | ₹-345cr | -456.0% |
| 2026 | ₹1,879cr | ₹1,598cr | ₹1,552cr | 85.0% |
| TTM | ₹1,909cr | ₹1,616cr | ₹1,583cr | 85.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
Data, tech and AI moving from ‘hype’ to ‘here and now’ Digital infrastructure, AI-enabled clinical tools and connected care models are reshaping how clinicians deliver care and how patients navigate the system. Hospitals, health systems and emerging health tech players are deploying AI to expand capacity, improve access and streamline workflows. The combined effect is to heighten expectations for real-time insight, p
Notably, majority of these manufacturing commitments were secured prior to the formal rollout of the MFN policy framework. The regulatory environment has also continued to evolve, with the US Food and Drug Administration (FDA) experiencing a period of organizational transition. Over the past year, the FDA has been impacted by workforce reductions, voluntary resignations and the departure or reassignment of several ex
The Company specializes in developing small molecules and biologics aimed at global commercialization, including in the Indian market. Rather than engaging in direct commercialization, SPARC licenses its proprietary innovations to pharmaceutical partners, while generating revenue through structured out-licensing agreements, encompassing royalties on product sales, upfront licensing fees, and milestone-based payments
Registrar & Transfer Agent MUFG Intime India Pvt Ltd (formerly known as Link Intime India Pvt Ltd.) C 101, 247 Park, LBS Marg, Vikhroli West, Mumbai - 400 083. Tel: +91 22 4918 6000 | +91 22 4918 6270 Fax: +91 22 4918 6060 E-mail: rnt.helpdesk@in.mpms.mufg.com Global Pharmaceutical Industry The global biopharmaceutical industry operated in a paradoxical environment: strong underlying demand and scientific innovation
of Shares % to total Up to 500 127810 88.8316 11684294 3.6005 501 - 1000 7514 5.2224 5845907 1.8014 1001 - 2000 4720 3.2805 6840651 2.1079 2001 - 3000 1398 0.9716 3547347 1.0931 3001 - 4000 543 0.3774 1948346 0.6004 4001 - 5000 453 0.3148 2113437 0.6512 5001 - 10000 739 0.5136 5398321 1.6635 10001 and above 702 0.4879 287143285 88.4820 Total 143879 100.00 324521588 100.00 11.5 Shareholding Pattern of the Company as o
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…